Obicetrapib is a small molecule commercialized by NewAmsterdam Pharma Company, with a leading Phase III program in Heterozygous familial hypercholesterolemia (heFH). According to Globaldata, it is involved in 22 clinical trials, of which 14 were completed, 3 are ongoing, 4 are planned, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Obicetrapib’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Obicetrapib is expected to reach an annual total of $453 mn by 2036 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Obicetrapib (AMG-899, DEZ-001, TA-8995) is under development for Alzheimer’s disease, atherosclerosis, dyslipidemia and heterozygous familial hypercholesterolemia (HeFH) and diabetes. It is administered orally as once daily formulation. The drug candidate acts by targeting cholesteryl ester transfer protein (CETP).
It was under development for was under development for the treatment of mild dyslipidemia by Amgen.
NewAmsterdam Pharma Company Overview
NewAmsterdam Pharma Company (NAP), a clinical stage biotechnology company focused on the research and development of transformative therapies for cardio-renal diseases. The company is headquartered in the Netherlands.
The company reported revenues of (Euro) EUR97.5 million for the fiscal year ended December 2022 (FY2022). The operating loss of the company was EUR67.6 million in FY2022, compared to an operating loss of EUR29.8 million in FY2021. The net loss of the company was EUR78.1 million in FY2022, compared to a net loss of EUR28.6 million in FY2021.
For a complete picture of Obicetrapib’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.